Antibiogram panel Designing. Dr f.Rashedmarandi. Penicillins. These penicillins are penicillinase-labile;hydrolyzed by staphylococcal penicillinase. Penicillinase-stable penicillin. ß- lactam /ß- lactamase inhibitor combinations. Cephems.
These penicillins are penicillinase-labile;hydrolyzed by staphylococcal penicillinase
III and IV are also referred to as “extended-spectrum cephalosporins.” This does not imply activity against ESBL-producing gram-negative bacteria.
The “susceptible” category implies that isolates are inhibited by the usually achievable concentrations of antimicrobial agent when the recommended dosage is used for the site of infection.
The “intermediate” category includes isolates with antimicrobial agent MICs that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates. The intermediate category implies clinical efficacy in body sites where the drugs are physiologically concentrated (e.g., quinolones and β-lactams in urine) or when a higher than normal dosage of a drug can be used (e.g., β-lactams). This category also includes a buffer zone, which should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations, especially for drugs with narrow pharmacotoxicity margins.
The “resistant” category implies that isolates are not inhibited by the usually achievable concentrations of the agent with normal dosage schedules, and/or that demonstrate zone diameters that fall in the range where specific microbial resistance mechanisms (e.g., beta- lactamases) are likely, and clinical efficacy of the agent against the isolate has not been reliably shown in treatment studies.
When fecal isolates of Salmonella and Shigella spp. are tested, only ampicillin, a quinolone, and trimethoprim-sulfamethoxazole should be reported routinely. In addition, chloramphenicol and a third- generation cephalosporin should be tested and reported for extraintestinal isolates of Salmonella spp.
Penicillin-susceptible staphylococci are also susceptible to other penicillins, cephems, and carbapenems approved for use by the FDA for staphylococcal infections. Penicillin-resistant, oxacillin- susceptible strains are resistant to penicillinase-labile penicillins, but susceptible to other penicillinase-stable penicillins, β-lactam/β-lactamase inhibitor combinations, relevant cephems, and carbapenems. Oxacillin-resistant staphylococci are resistant to all currently available β-lactam antibiotics. Thus, susceptibility or resistance to a wide array of β-lactam antibiotics may be deduced from testing only penicillin and oxacillin.
Routine testing of other penicillins, β-lactamase inhibitor combinations, cephems, and carbapenems is not advised.
The cefoxitin disk test is the preferred method for testing S. aureus, S. lugdunensis, and coagulase-negative staphylococci for resistance to the penicillinase-stable penicillins. Cefoxitin is used as a surrogate for detecting oxacillin resistance; report oxacillin as susceptible or resistant based on the cefoxitin result.
For Enterococcusspp., cephalosporins,aminoglycosides (except for high-level resistance screening), clindamycin, and trimethoprim-sulfamethoxazolemay appear active in vitro, but are not effective clinically, and isolates should not be reported as susceptible.
ß lactamase - enterococcus :susceptible to penicillin,ampicillin,amoxicillin,ampicillin sulbactam,amoxicillin-clavulanic acid,piperacillin,piperacillin tazobactam
Prediction with: penicillin disk test
ß lactamase + enterococcus : Resistant to
penicillin,ampicillin,amoxicillin,ampicillin sulbactam,amoxicillin-clavulanic acid,piperacillin,piperacillin tazobactam
a β-lactamase test is the only reliable test
for detecting β-lactamase-producing Enterococcus spp.
For blood and cerebrospinal fluid isolates(Enterococci), a β-lactamase test is also recommended.
Notice: combined therapy with high- dose penicillin or high-dose ampicillin or vancomycin or teicoplanin plusgentamicin or streptomycin for bactericidal action
is usually indicated for serious enterococcal infections, such as endocarditis.
Because of limited alternatives, chloramphenicol, erythromycin, tetracycline (or doxycycline or minocycline), and rifampin may be tested for vancomycin-resistant enterococci (VRE),
consultation with an infectious disease practitioner is recommended.
penicillin and cefotaxime or ceftriaxone or meropenem
Vancomycin (MIC or Disk)
Oxacillin Disk Screening Test
zone ≤ 19 mm =» MIC of penicillin,cefotaxime,ceftriaxone
. Susceptibility testing of penicillins and other β-lactams approved by FDA for treatment of Streptococcus pyogenes or Streptococcus agalactiae is not necessary for clinical purposes and need not be done routinely, since as with vancomycin, resistant strains have not been recognized. Interpretive criteria are provided for pharmaceutical development, epidemiology, or monitoring for emerging resistance. Any strain found to be nonsusceptible should be referred to a reference laboratory for confirmation.
Recommendations for intrapartum prophylaxis for Group B streptococci are penicillin or ampicillin. While cefazolin is recommended for penicillin-allergic women at low risk for anaphylaxis, those at high risk for anaphylaxis may receive clindamycin or erythromycin. Group B streptococci are susceptible to ampicillin, penicillin, and cefazolin, but may be resistant to clindamycin and/or erythromycin. When a Group B streptococcus is isolated from a pregnant woman with severe penicillin allergy (high risk for anaphylaxis), clindamycin and erythromycin should be tested and reported.
Strains of Klebsiella spp. E. coli, and P. mirabilis that produce ESBLs may be clinically resistant to therapy with penicillins, cephalosporins, or aztreonam, despite apparent in vitro susceptibility to some of these agents.
resistant for all penicillins, cephalosporins, and aztreonam.
Penicillin-susceptible staphylococci are also susceptible to other penicillins, cephems, and carbapenems approved for use by the FDA for staphylococcal infections. (slide4)
Thus, interpretation should be reported assusceptibility or resistance to a wide array of β-lactam antibiotics may be deduced from testing
only penicillin and oxacillin.
Routine testing of other penicillins, β-lactamase inhibitor combinations, cephems, and carbapenems is not advised.
Of the penicillinase-stable penicillins, oxacillin is preferred for in vitro testing. Oxacillin
susceptibility test results can be applied to the other penicillinase-stable penicillins, i.e., cloxacillin,dicloxacillin,flucloxacillin,methicillin, and nafcillin.
Most resistance to oxacillin in staphylococci is mediated by the mecA gene, which directs the production
of a supplemental penicillin-binding protein, PBP 2a, and is expressed either homogeneously or
heterogeneously. Homogeneous resistance is easily detected with standard testing methods, whereas
heterogeneous expression may be more difficult to
detect with some methods because only a fraction of
the population (e.g., 1 in 100 000 cells) expresses the resistance phenotype
Report isolates of staphylococci that carry the mecA, or that produce PBP 2a, the mecA gen product, as
Staphylococcus aureus produce β-lactamase, and the testing of the 10-unit penicillin disk instead of the ampicillin disk is preferred.
Penicillin should be used to test the susceptibility of all β-lactamase-labile penicillins, such as ampicillin, amoxicillin, azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin.Likewise, a positive β-lactamase test predicts resistance to these agents. For oxacillin-resistant staphylococci, report as resistant or do not report.
Resistant strains are reliably detected by the microdilution reference method, the disk diffusion method and the vancomycin agar screen test when the tests are incubated for a full 24 hours at 35 ± 2 ºC.
All staphylococcal isolates for which vancomycin zone diameters are 14 mm or less should be tested by a reference MIC method. The disk diffusion procedure will not differentiate strains with reduced susceptibility to vancomycin (MICs 4-8 µg/mL) from susceptible strains (MIC range 0.5 to 2 µg/mL) even when incubated for 24 hours. Additionally, vancomycin- resistant S. aureus (VRSA) strains (MICs ≥16 µg/mL) may produce only subtle growth around a vancomycin disk. A BHI
vancomycin agar screen plate containing 6 µg/mL of vancomycin, such as that used for detection of vancomycin-resistant enterococci, may be inoculated to enhance the sensitivity of detecting vancomycin intermediate and vancomycin-resistant strains of S. aureus. Send any staphylococci determined to have an elevated MIC to vancomycin (≥4 µg/mL) to a reference laboratory.
Staphylococcus diameters are 14 mm or less should be tested by a reference MIC method. spp. may develop resistance during prolonged therapy with quinolones. Therefore, isolates that are initially susceptible may become resistant within three to four days after initiation of therapy. Testing of repeat isolates may be warranted.
The results of disk diffusion tests using a 30-μg cefoxitin disk and alternate breakpoints can be used to predict mecA-mediated oxacillin resistance in staphylococci. The cefoxitin disk
test is equivalent to oxacillin MIC tests in sensitivity and specificity for S. aureus. For coagulasenegative
staphylococci, the cefoxitin disk test has equivalent sensitivity to oxacillin MIC tests but
greater specificity, i.e., the cefoxitin disk test more accurately identifies oxacillin-susceptible strains
than the oxacillin MIC test.
WARNING: diameters are 14 mm or less should be tested by a reference MIC method. For Enterococcus spp., cephalosporins, aminoglycosides (except for high-level resistance screening), clindamycin, and trimethoprim- sulfamethoxazole may appear active in vitro, but are not effective clinically, and isolates should not be reported as susceptible.
Synergy between ampicillin, penicillin, or vancomycin and an aminoglycoside can be predicted for enterococci by using a high-level aminoglycoside (gentamicin and streptomycin) screening test. Other aminoglycosides need not be tested, because their activities against enterococci are not superior to gentamicin and streptomycin.
high-level( AG) resistance screening(HLAR):
Gentamycin 120µ :6=R 7-9=Inconclusive ≥10=S
Because of limited alternatives, and an aminoglycoside can be predicted for enterococci by using a high-level aminoglycoside (gentamicin and streptomycin) screening test. Other aminoglycosides need not be tested, because their activities against enterococci are not superior to gentamicin and streptomycin.chloramphenicol, erythromycin, tetracycline (or doxycycline or minocycline), and rifampin may be used for vancomycin- resistant enterococci (VRE), and consultation with an infectious disease practitioner is recommended.
Penicillin susceptibility may be used to predict the susceptibility to ampicillin, amoxicillin, ampicillin-sulbactam, amoxicillin-clavulanic acid,piperacillin,and piperacillin-tazobactam for non-β-lactamase-producing enterococci. Ampicillin susceptibility can be used to predict imipenem susceptibility, provided the species is confirmed to be E.faecalis.
Ampicillin is the class representative for ampicillin and amoxicillin.Ampicillin results may be used to predict susceptibility to amoxicillin-clavulanic acid, ampicillin-sulbactam, piperacillin, and piperacillin-
tazobactam among non-β-lactamase-producing enterococci.
The “susceptible” category for penicillin or ampicillin implies the need for high-dose therapy for serious enterococcal infections.
Enterococcal endocarditis requires combined therapy with high-dose penicillin or high-dose ampicillin, or vancomycin or teicoplanin plus
gentamicin or streptomycin for bactericidal action.
Because ampicillin or penicillin resistance among enterococci due to β-lactamase production is not reliably detected using routine disk or dilution methods, a direct, nitrocefin-based β-lactamase test is recommended for blood and cerebrospinal fluid isolates. A positive β-lactamase test predicts resistance to penicillin, as well as amino-,
carboxy-, and ureidopenicillins.
When testing vancomycin against enterococci, plates should be held a full 24 hours and examined using transmitted light; the presence of a haze or any growth within the zone of inhibition indicates resistance. Organisms with intermediate zones should be tested by an MIC method .
Oxacillin Screening Plates
The oxacillin salt-agar screening-plate procedure can be used in addition to the dilution methods described above for the detection of MRSA. Perform the test by inoculating a S. aureus isolate onto Mueller-Hinton agar that has been supplemented with NaCl (4% w/v; 0.68 mol/L) and that contains 6 μg oxacillin/mL. Inoculate the agar from a direct colony suspension equivalent to a 0.5 McFarland standard using either a 1-μL loop or a swab. Using a 1-μL loop, spread the inoculum in an area 10 to 15 mm in diameter. Alternatively, using a swab, express excess fluid as for the disk diffusion test and then spot an area at least 10 to 15 mm in diameter or streak an entire quadrant. Incubate the plate at temperatures at 35
± 2 °C (testing at temperatures above 35 °C may not detect MRS) for 24 hours and examine carefully with transmitted light for evidence of small colonies (>1 colony) or a light film of growth, indicating oxacillin resistance .Do not reuse plates after incubation.
Thank you susceptible or resistant.
Health Reference Laboratory